[go: up one dir, main page]

WO2009089399A3 - Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection - Google Patents

Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection Download PDF

Info

Publication number
WO2009089399A3
WO2009089399A3 PCT/US2009/030513 US2009030513W WO2009089399A3 WO 2009089399 A3 WO2009089399 A3 WO 2009089399A3 US 2009030513 W US2009030513 W US 2009030513W WO 2009089399 A3 WO2009089399 A3 WO 2009089399A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
toll
receptor
methods
coreceptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/030513
Other languages
French (fr)
Other versions
WO2009089399A2 (en
Inventor
Jinzhong Zhang
Keith Wayne Ward
Toan Vo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch and Lomb Inc
Original Assignee
Bausch and Lomb Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch and Lomb Inc filed Critical Bausch and Lomb Inc
Publication of WO2009089399A2 publication Critical patent/WO2009089399A2/en
Publication of WO2009089399A3 publication Critical patent/WO2009089399A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions for treating or controlling degeneration of at least a component of the human optic nerve system comprise an antagonist to a toll-like receptor, a coreceptor thereof, or a combination thereof. The compositions can also include an anti- inflammatory medicament. Such compositions can be administered to provide neuroprotection to a patient suffering from an ocular disease, such as glaucoma, AMD, DR, or retinitis pigmentosa.
PCT/US2009/030513 2008-01-10 2009-01-09 Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection Ceased WO2009089399A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2015908P 2008-01-10 2008-01-10
US61/020,159 2008-01-10

Publications (2)

Publication Number Publication Date
WO2009089399A2 WO2009089399A2 (en) 2009-07-16
WO2009089399A3 true WO2009089399A3 (en) 2009-10-08

Family

ID=40790420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/030513 Ceased WO2009089399A2 (en) 2008-01-10 2009-01-09 Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection

Country Status (1)

Country Link
WO (1) WO2009089399A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX387728B (en) 2010-06-03 2025-03-18 Pharmacyclics Llc THE USE OF BRUTON TYROSINE KINASE (BTK) INHIBITORS.
BR112015001690A2 (en) 2012-07-24 2017-11-07 Pharmacyclics Inc mutations associated with resistance to bruton tyrosine kinase inhibitors (btk)
ITUB20169937A1 (en) 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF PIGMENTAL RETINITIS
AU2017277647B2 (en) 2016-06-08 2023-07-27 President And Fellows Of Harvard College Engineered viral vector reduces induction of inflammatory and immune responses
WO2019094548A1 (en) 2017-11-08 2019-05-16 President And Fellows Of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
EP4175636A2 (en) * 2020-07-02 2023-05-10 The United States of America, as represented by the Secretary, Department of Health and Human Services Cyclic compounds for use in treating retinal degeneration

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412641A2 (en) * 1989-06-22 1991-02-13 Teijin Limited Use of vitamin D in retinopathy
US20030216431A1 (en) * 2002-05-17 2003-11-20 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
WO2006102408A2 (en) * 2005-03-22 2006-09-28 Children's Hospital Medical Center Methods and compositions for the modulation of immune responses and autoimmune diseases
WO2006120696A2 (en) * 2005-02-21 2006-11-16 Rajeev Raut An improved pharmaceutical composition
WO2007109813A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2007133800A2 (en) * 2006-05-15 2007-11-22 University Of Kentucky Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration
WO2008062288A2 (en) * 2006-11-23 2008-05-29 Cadila Pharmaceuticals Limited Poly-tlr antagonist
WO2009006141A2 (en) * 2007-07-05 2009-01-08 Bausch & Lomb Incorporated Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof
WO2009015107A1 (en) * 2007-07-20 2009-01-29 Yeda Research And Development Co. Ltd. Modulation of toll-like receptors for controlling neurogenesis

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412641A2 (en) * 1989-06-22 1991-02-13 Teijin Limited Use of vitamin D in retinopathy
US20030216431A1 (en) * 2002-05-17 2003-11-20 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
WO2006120696A2 (en) * 2005-02-21 2006-11-16 Rajeev Raut An improved pharmaceutical composition
WO2006102408A2 (en) * 2005-03-22 2006-09-28 Children's Hospital Medical Center Methods and compositions for the modulation of immune responses and autoimmune diseases
WO2007109813A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2007133800A2 (en) * 2006-05-15 2007-11-22 University Of Kentucky Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration
WO2008062288A2 (en) * 2006-11-23 2008-05-29 Cadila Pharmaceuticals Limited Poly-tlr antagonist
WO2009006141A2 (en) * 2007-07-05 2009-01-08 Bausch & Lomb Incorporated Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof
WO2009015107A1 (en) * 2007-07-20 2009-01-29 Yeda Research And Development Co. Ltd. Modulation of toll-like receptors for controlling neurogenesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NEUBAUER A S ET AL: "Detecting chloroquine retinopathy: electro-oculogram versus colour vision.", THE BRITISH JOURNAL OF OPHTHALMOLOGY JUL 2003, vol. 87, no. 7, July 2003 (2003-07-01), pages 902 - 908, XP002534831, ISSN: 0007-1161 *
SUN SIQUAN ET AL: "TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders", INFLAMMATION & ALLERGY DRUG TARGETS, BENTHAM SCIENCE PUBLISHERS, vol. 6, no. 4, 1 December 2007 (2007-12-01), pages 223 - 235, XP009108385, ISSN: 1871-5281 *

Also Published As

Publication number Publication date
WO2009089399A2 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
WO2011014587A3 (en) Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
WO2010077883A3 (en) Antagonists of lysophosphatidic acid receptors
WO2010141768A3 (en) Polycyclic antagonists of lysophosphatidic acid receptors
WO2010068775A3 (en) Alkyne antagonists of lysophosphatidic acid receptors
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
WO2011041461A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011041694A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
WO2009046446A3 (en) Dendrimers for sustained release of compounds
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
PH12012502373A1 (en) Aminopyrimidine derivatives as lrrk2 modulators
WO2008147883A8 (en) Prevention and treatment of complement-associated eye conditions
MX2012004848A (en) Tricyclic heterocyclic compounds.
WO2009089399A3 (en) Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
WO2011035335A3 (en) Stabilized liquid and lyophilized adamts13 formulations
EP2004188A4 (en) Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
WO2008049842A3 (en) Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders
WO2007130842A3 (en) Combination therapy for diseases involving angiogenesis
WO2009038673A3 (en) Thieno-and furo-pyrimidine modulators of the histamine h4 receptor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09700673

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09700673

Country of ref document: EP

Kind code of ref document: A2